PDA

View Full Version : Palbociclib expanded access program now open to eligible U.S. patients with HR+, HER2

News
08-22-2014, 04:00 AM
Pfizer Inc. has announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib.

More... (http://www.medicalnewstoday.com/releases/281404.php)